AN2 Therapeutics Reports Third Quarter 2022 Financial Results and Provides Business Updates
November 09, 2022 16:05 ET
|
AN2 Therapeutics, Inc.
U.S. Enrollment Ongoing in EBO-301 Pivotal Phase 2/3 Clinical Trial of Epetraborole in Treatment-Refractory MAC Lung Disease; Plan to Include Japanese Patients in TrialAwarded Contract from NIAID...
AN2 Therapeutics to Present at Upcoming Investor Conferences
November 02, 2022 16:10 ET
|
AN2 Therapeutics, Inc.
MENLO PARK, Calif., Nov. 02, 2022 (GLOBE NEWSWIRE) -- AN2 Therapeutics, Inc. (Nasdaq: ANTX), a clinical-stage biopharmaceutical company focused on developing treatments for rare, chronic, and...
AN2 Therapeutics to Present New Epetraborole Data at IDWeek 2022
October 19, 2022 08:00 ET
|
AN2 Therapeutics, Inc.
Enrollment Ongoing in Phase 2/3 Pivotal Trial of Epetraborole in Treatment- Refractory MAC Lung Disease MENLO PARK, Calif., Oct. 19, 2022 (GLOBE NEWSWIRE) -- AN2 Therapeutics, Inc. (Nasdaq: ANTX),...
AN2 Therapeutics Provides Update on Epetraborole Ex-U.S. Development Plan in Treatment-Refractory MAC Lung Disease
October 06, 2022 07:00 ET
|
AN2 Therapeutics, Inc.
Epetraborole Data from Recently Completed Phase 1 Study in Japanese Subjects Supports Use of Once Daily, 500 mg Dose in Japanese PatientsTreatment-Refractory MAC Lung Disease Clinical Development...
NIH Awards Contract to AN2 Therapeutics Valued Up to $17.8 Million
September 29, 2022 07:00 ET
|
AN2 Therapeutics, Inc.
Non-dilutive funding will drive synergies with existing epetraborole development program for NTM lung diseaseAward leverages AN2 Therapeutics expertise and commitment to address urgent unmet global...
AN2 Therapeutics to Present at H.C. Wainwright 24th Annual Global Investment Conference
August 29, 2022 07:00 ET
|
AN2 Therapeutics, Inc.
MENLO PARK, Calif., Aug. 29, 2022 (GLOBE NEWSWIRE) -- AN2 Therapeutics, Inc. (Nasdaq: ANTX), a clinical-stage biopharmaceutical company focused on developing treatments for rare, chronic, and...
AN2 Therapeutics Reports Second Quarter 2022 Financial Results and Provides Business Updates
August 11, 2022 16:10 ET
|
AN2 Therapeutics, Inc.
Enrolling U.S. Patients in the EBO-301 Pivotal Phase 2/3 Trial of Epetraborole in Treatment-Refractory MAC Lung Disease; Topline Results from Phase 2 Part of Trial Expected in Mid-2023Completed...
AN2 Therapeutics Initiates Pivotal Phase 2/3 Trial Evaluating Epetraborole for Treatment-Refractory MAC Lung Disease
June 29, 2022 07:00 ET
|
AN2 Therapeutics, Inc.
AN2 is developing epetraborole as a once-daily, orally administered treatment with a novel mechanism of action for patients with NTM lung disease, with an initial focus on treatment-refractory MAC...
AN2 Therapeutics Reports First Quarter 2022 Financial Results and Provides Business Updates
May 10, 2022 16:10 ET
|
AN2 Therapeutics, Inc.
On Track for Several Milestones in 2022, and Supported by Strong Balance Sheet from Upsized Initial Public Offering Continued Progress Advancing Epetraborole Clinical Program with Enrollment for...
AN2 Therapeutics Announces Pricing of Upsized Initial Public Offering
March 24, 2022 22:32 ET
|
AN2 Therapeutics, Inc.
MENLO PARK, Calif., March 24, 2022 (GLOBE NEWSWIRE) -- AN2 Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on developing treatments for rare, chronic, and serious infectious...